Alzheimer Disease

Anavex scales up synthesis of ANAVEX 2-73 for Phase 1 Alzheimer's disease study

Published in Drug Law Weekly, February 17th, 2009

Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB ("Syntagon") for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is scheduled to commence Phase 1 studies in 2009.

"The agreement with Syntagon is another important and tangible step towards the further development of ANAVEX 2-73 and commencement of Phase 1 clinical trials," said Harvey Lalach, President of ANAVEX. "We are very pleased with our progress to date with the compound, which shows enormous potential to modify and reverse the effects of Alzheimer's disease. We...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2009-02-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry